Related references
Note: Only part of the references are listed.Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety
Sanjana Ballal et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study
Nilofer S. Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
Jonathan Strosberg et al.
CLINICAL CANCER RESEARCH (2020)
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Sandip P. Patel et al.
CLINICAL CANCER RESEARCH (2020)
The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts
Sara Lundsten et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study
Jonathan Strosberg et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs).
Daniel M. Halperin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First US Prospective, Reader-Masked Clinical Trial
Ebrahim S. Delpassand et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)
Enrique Grande et al.
ONCOLOGIST (2020)
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study
Janice M. Mehnert et al.
CANCER (2020)
Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS).
Nick Pavlakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).
Arvind Dasari et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Etctn 10388: A phase I trial of triapine and lutetium Lu 177 dotatate in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Aman Chauhan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Targeted α-Emitter Therapy of Neuroendocrine Tumors
Jolanta Kunikowska et al.
SEMINARS IN NUCLEAR MEDICINE (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
J. Capdevila et al.
ANNALS OF ONCOLOGY (2020)
Exploring the role of survivin in neuroendocrine neoplasms
Ahmad Hanif et al.
Oncotarget (2020)
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
Jianming Xu et al.
LANCET ONCOLOGY (2020)
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
Jianming Xu et al.
LANCET ONCOLOGY (2020)
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial
Jianming Xu et al.
CLINICAL CANCER RESEARCH (2019)
Combination of everolimus and lu-177 PRRT in treatment of G1-2 neuroendocrine tumors (NET): Phase 1-2 study.
Ali Husain Aljubran et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo
Brian H. White et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Clinical efficacy and toxicity data on phase I study of fosbretabulin in combination with everolimus in neuroendocrine tumors.
Aman Chauhan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).
Jaume Capdevila et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).
Emily K. Bergsland et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The SUNEVO (GETNE-1408) trial to evaluate the activity and safety of the combination of sunitinib with evofosfamide (TH-302) in patients with G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naive for systemic treatment: A phase II study of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumors (GETNE).
Enrique Grande et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Ming Yi et al.
MOLECULAR CANCER (2019)
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan
Diane Reidy-Lagunes et al.
CLINICAL CANCER RESEARCH (2019)
The next generation of peptide receptor radionuclide therapy
Tessa Brabander et al.
ENDOCRINE-RELATED CANCER (2019)
1404TiPHORMONET: Study of tamoxifen in well differentiated neuroendocrine tumours and hormone receptor positive expression
M Barros et al.
ANNALS OF ONCOLOGY (2019)
Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Kerry A. Whalen et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Targeted Alpha Particle Therapy for Neuroendocrine Tumours: The Next Generation of Peptide Receptor Radionuclide Therapy
Shaunak Navalkissoor et al.
NEUROENDOCRINOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors
Jingjing Zhang et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor
Nupur K. Purohit et al.
Oncotarget (2018)
Evans Blue Attachment Enhances Somatostatin Receptor Subtype-2 Imaging and Radiotherapy
Rui Tian et al.
THERANOSTICS (2018)
First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.
Melissa Lynne Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors
Darren S. Sigal et al.
Oncotarget (2018)
Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study
S. Pusceddu et al.
ANNALS OF ONCOLOGY (2017)
Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors
Sara Pusceddu et al.
FUTURE ONCOLOGY (2017)
Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET).
Jennifer A. Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Somatostatin Receptor Antagonists for Imaging and Therapy
Melpomeni Fani et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
A multicohort phase II study of durvalumab plus tremelimumab for the treatment of patients (PTS) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or lung origin (the DUNE trial-GETNE1601-).
Ignacio Matos Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice
Johan Spetz et al.
BMC CANCER (2017)
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0, Tyr3] octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
Tessa Brabander et al.
CLINICAL CANCER RESEARCH (2017)
Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs
Simron Singh et al.
JOURNAL OF GLOBAL ONCOLOGY (2017)
Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models
Simone U. Dalm et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
A phase II study of axitinib in advanced neuroendocrine tumors
J. R. Strosberg et al.
ENDOCRINE-RELATED CANCER (2016)
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao et al.
LANCET (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
Julie Nonnekens et al.
THERANOSTICS (2016)
NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study
Phillip G. Claringbold et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2015)
213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
C. Kratochwil et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study
Damian Wild et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Recommendations for management of patients with neuroendocrine liver metastases
Andrea Frilling et al.
LANCET ONCOLOGY (2014)
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn E. Caplin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches
Kjell Oberg et al.
CLINICAL CANCER RESEARCH (2013)
Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells
Kathrin Zitzmann et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Attenuation of the Retinoblastoma Pathway in Pancreatic Neuroendocrine Tumors Due to Increased Cdk4/Cdk6
Laura H. Tang et al.
CLINICAL CANCER RESEARCH (2012)
First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas
Jonathan R. Strosberg et al.
CANCER (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma Model
Tai-Gyu Kim et al.
CLINICAL AND VACCINE IMMUNOLOGY (2010)
A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)
Dietmar W. Siemann et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Involvement of centrosome amplification in radiation-induced mitotic catastrophe
Helen Dodson et al.
CELL CYCLE (2007)
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide:: The Rotterdam experience
R Valkema et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Share Paper
